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Smart active antibiotic nanocarriers with
protease surface functionality can overcome
biofilms of resistant bacteria†
Paul J. Weldrick, a Matthew J. Hardman b and Vesselin N. Paunov *a
Treating bacterial infections with species demonstrating antibiotic resistance to the chosen antibiotic is
often hindered due to the ability of certain bacteria to grow biofilms where they can effectively hide and
resist the antibiotic action. We report an innovative solution for overcoming both antibiotic resistance
and biofilm formation by designing active antibiotic nanocarriers with protease surface functionality.
We show that this active nanocarrier of common antibiotics can efficiently degrade biofilms of resistant
bacteria and bypass their defences. The cationic protease coating, whilst allowing electrostatic adhesion
of the nanoparticle to the cell, simultaneously also degrades the biofilm and helps the active nanocarriers to
reach the entrapped bacterial cells. We demonstrated this concept by encapsulating Penicillin G and
Oxacillin into shellac nanoparticles, subsequently coated with a serine endo-peptidase protease, Alcalase
2.4 L FG. We show for the first time that these active nanocarriers can destroy biofilms of S. aureus resistant
to Penicillin G and are significantly more effective in killing the bacterial cells within compared to an
equivalent concentration of free antibiotic. The approach of concentrating the antibiotic by encapsulating it
into a nanocarrier allows a localised delivery of the antibiotic to the anionic cell wall, facilitated by coating
the NPs with a cationic protease. This approach allowed the antibiotic to restore its effectiveness against
S. aureus, characterised as resistant to the same antibiotic as well as to cause a rapid degradation of the
bacterial biofilm. This approach could be potentially used to revive old antibiotics which have already limited
clinical use due to developed resistance.
Introduction
Penicillin is a commonly administered antibiotic used to treat
staphylococci and streptococci infections.1 Penicillin is part of
the beta-lactam cyclic amine antibiotic family, and all antibiotics
in the family used the same bacterial cell wall growth inhibition to
kill bacteria.2 There is a range of resistance mechanisms that
bacteria have evolved against such antibiotics, some of which are
discussed in the ESI.† 3–7 The production of beta-lactamase (which
hydrolyses penicillin into penicilloic acid) is common in Staphy-
lococcus aureus, a pathogen that can cause infection in skin, lungs
and blood.8 Most strains of S. aureus are now resistant to first-
generation penicillin’s and so second-generation penicillin’s such
as oxacillin, nafcillin and methicillin are administered.9 A report
by the World Health Organisation in 2014 stated that antibiotic
resistance is a growing worldwide threat to public health,
driven largely by the lack of new therapeutic agents for treating
bacterial infections.10 Overcoming resistance to beta-lactam
antibiotics is most commonly achieved by using a beta-
lactamase inhibitor such as clavulanic acid, which can bind
to the active site of beta-lactamases and provide form a stable
acyl enzyme complex, thereby inhibiting the enzyme.11 Another
approach is to target the pathways of Gram-positive cell wall
production. Tunicamycin and ticlopidine have been shown to
inhibit the enzymatic pathway for teichoic acid, a key compo-
nent of the Gram-positive cell wall.12
The ability of bacteria to form biofilms further complicates
their treatment.13 A biofilm is an extracellular polymeric
substance (EPS) which is secreted by bacterial communities
and surrounds them in a protective layer.14 EPS is a structured
matrix of exopolysaccharides, lipids, nucleic acids and
protein.15 Biofilms protect the bacterial cells within and allow
them to tolerate treatments due to the quenching of antimi-
crobial agents at concentrations that would otherwise kill
planktonic cells.16 Impaired diffusion of antimicrobial agents
through the EPS increases the tolerance to treatments.17 Oppor-
tunistic pathogens, such as S. aureus, can cause chronic infection
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in dermal wounds, potentially caused by a combination of
biofilm production and antimicrobial resistance.18,19
Nanoparticles (NPs) have been investigated for their anti-
biofilm action and ability to overcome antimicrobial resistance.
A variety of different NPs such as Au NPs, silica NPs, Mg(OH)2
NPs and CuONPs have all been shown to demonstrate
increased toxicity towards bacteria.20–24,45 AgNPs has been
researched in anti-biofilm treatments due to the silver ions
intrinsic antimicrobial property.25,43 Nanocarriers for anti-
microbial agents have also been shown to increase their
efficacy against a wide range of microorganisms, including
resistant species26–29 and deliver drugs specifically to a bacterial
target.35,42–44 This can potentially reduce unwanted drug inter-
action in healthy tissue and lower general toxicity.36 They
can also protect the antimicrobial agent from premature
degradation and inactivation.37,38 Biofilm degradation has been
investigated using a range of biologically inspired hydrolases,
amylases and proteases.30,46 The disruption of the biofilm
formation by NPs can improve the ability of antimicrobial
agents to kill the cells within.28 Proteases can be particularly
useful for degrading biofilms due to their ability to hydrolyse
ESP matrix proteins and bacterial adhesins.31–33 Disruption of
the synthesis of biofilm formation using small molecules to
inhibit key signalling pathways such as c-dis-GMP and indole
has also been investigated.34
In this study, we present a novel concept for an active
nanocarrier delivery of Penicillin G and Oxacillin to biofilms
by their encapsulation into a protease-functionalised shellac
NPs. The NPs surface coating of a cationic protease, Alcalase
2.4 L FG, performs a dual purpose to both degrade the
biofilms and increase the electrostatic interaction between
the cationic NPs and the anionic cell walls of the entrapped
bacteria. Fig. 1A illustrates the scheme for fabrication of the
composite shellac NPs, and Fig. 1B shows their mechanism
of action. Fig. S1 (see ESI†) provides a detailed information
about the individual components of the NP and the chemical
structure of the antibiotics. S. aureus was chosen as the
model pathogen for its ability to form a biofilm. This
S. aureus strain (ATCCs 29213t) was selected due to its
resistance to Penicillin G (PenG) and its sensitivity to oxacil-
lin (Oxa). The gene blaZ which produces the protein product
beta-lactamase (EC number: 3.5.2.6) was shown to be in the
genome of this strain, as confirmed by the ATCC One Codex
depository.39 Additionally, this stain does not carry the mecA
gene which encodes an altered penicillin-binding protein
(PBP2a) which confers resistance to oxacillin due to reduced
beta-lactamase affinity.40
Here we aim to prove that its antimicrobial resistance can
be overcome by using highly concentrated antibiotics loaded
inside the shellac NPs, both in planktonic cells and biofilm
treatment experiments. NP characterisation, including prepara-
tion, encapsulation efficiency, release kinetics and Alcalase
functionalisation of PenG/Oxa-loaded shellac NPs can be
found in ESI.†
Fig. 1 (A) Schematic for the synthesis of functionalized shellac NPs as nanocarriers for Benzylpenicillin or Oxacillin (PenG or Oxa). The PenG/Oxa-
loaded shellac NPs are sterically stabilized with Poloxamer 407 (P407) and have cationic surface functionality achieved by coating with the cationic
protease Alcalase 2.4. L FG. (B) Diagram of the mechanism of action for PenG/Oxa-loaded Alcalase functionalized shellac NPs. Alcalase coating degrades
the biofilm exposing the cells and allowing the cationic NPs to adhere to the cell surface. Gradual release of antibiotic is highly localised and results in
rapid cell death.
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Results and discussion
A formulation of 0.25 wt% shellac NPs loaded with 0.1 wt%
PenG/Oxa and coated with 0.2 wt% P407 and subsequently with
0.2 wt% Alcalase was chosen as the stock treatment for testing
against S. aureus. Here, we show that PenG and Oxacillin
encapsulated in the shellac NPs, functionalised with a surface
coating of a cationic protease, are significantly more effective
than the free antibiotics administered at equivalent concen-
tration. We aim to demonstrate that antibiotics encapsulated
into such active NPs have an increased efficacy that can over-
whelm the enzymatic inhibition of the antibiotic (specifically
PenG). This is investigated on S. aureus in planktonic and
biofilm forms.
Firstly, we confirmed S. aureus as a suitable candidate by
performing an antimicrobial susceptibility screen using VITEKs2
ID and AST microwell cards (Fig. S16, ESI†). Table S2 (ESI†) shows
the range of antibiotics tested for susceptibility and their inter-
pretation as resistant or susceptible. This S. aureus strain was
confirmed to be susceptible to Oxa and resistant to PenG. This
was verified using antimicrobial disk diffusion for both Oxa and
PenG (Fig. S17, ESI†). The zone diameter breakpoint for PenG
is o26 mm, as stated by the European Committee on Anti-
microbial Susceptibility Testing (EUCAST) testing breakpoint
tables.41
There is a clear zone of inhibition diameter around the
oxacillin disk (27 mm) confirming its susceptibility to that
antibiotic. Most staphylococci are now beta-lactamase producers
and this is the mechanism of resistance to penicillin antibio-
tics, requiring treatment with isoxazolylpenicillins (e.g. oxacil-
lin). To confirm this a simple beta-lactamase detection strip
was used on a S. aureus suspension (Fig. S18, ESI†). This test is
based on beta-lactamase hydrolysing the beta lactam ring
(present in PenG and all penicillin antibiotics) into penicillioc
acid. A yellow solution was generated after 10 min indicating
the presence of an acid in the solution (acid–base indicator),
and therefore beta-lactamase produced by S. aureus.
The effectiveness of the base formulation of 0.25 wt%
shellac–0.2 wt% P407–0.1 wt% PenG/Oxa–0.2 wt% Alcalase
NPs (0.1 wt% PenG-NPs or 0.1 wt% Oxa-NPs) was tested against
the equivalent concentration of free PenG or Oxa (0.1 wt%)
using a time-kill assay.
Fig. 2 Time kill assays against S. aureus. Growth control (untreated). (A) 0.1 wt% free PenG (Penicillin G) (B) and 0.1 wt% Oxa (Oxacillin) were compared
to the same antibiotic concentration encapsulated into Alcalase-coated shellac NPs. o0.05, **P o 0.01, ***P o 0.001 compared to the free antibiotic.
Table S4 (ESI†) shows the statistical analysis P-values. (C) S. aureus MIC and MBC of free PenG/Oxa, encapsulated PenG/Oxa NPs and individual
constituents of the NP. 0.25 wt% shellac–0.2 wt% P407–0.1 wt% PenG/Oxa-0.2 wt% Alcalase was the stock treatment solution. Treatment
concentrations lower than this were 2-fold dilutions from the stock. ‘‘4’’ indicates that a greater and ‘‘o’’ a lower concentration is needed to either
inhibit or kill S. aureus. The MIC was determined to be the lowest concentration of active antimicrobial agent which inhibited the growth of each strain.
The MBC was the lowest concentration in which no viable cells were detected after streaking the contents onto fresh MHA plates. (D) Beta lactamase
activity of S. aureus after 1 to 3 h PenG, PenG-NP and Alcalase treatments expressed per mg of protein. Experiment was capped at 3 hours due to lack of
remaining cells to analyse. Unit definition: 1 Unit Beta lactamase activity = amount of enzyme that generates 1 mmol of nitrocefin per minute at pH 7 at
25 1C.
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Fig. 2A and B show that S. aureus starting at a concentration
of 1  106 cells per mL increased to approximately 1  109 cells
per mL when untreated. Treatment with 0.1 wt% free PenG had
a minimal effect on bacterial growth, with 1  107 cells after a
24 h incubation time, confirming the resistance of the cells to
this treatment (Fig. 2A). However, when treated with 0.1 wt%
PenG-NPs there were no viable cells after 4 h, a 4 log+ reduction
from the free PenG sample. This confirms the PenG-loaded NPs
are overcoming the resistance and restoring the effectiveness of
the antibiotic. This is due to the high concentration of the
agent within the NPs cores, which is localised onto the bacterial
cell wall due to the electrostatic attraction of the cationic NPs to
the anionic surface of the bacterial cell. Fig. 2B shows the
same time kill assay performed against S. aureus, this time with
0.1 wt% free Oxa and 0.1 wt% Oxa-NPs. As described earlier,
this strain of S. aureus is susceptible to Oxa and so after 6 h
treatment with 0.1 wt% Oxa (free) there were no viable cells
detected. However, the 0.1 wt% Oxa-NPs were faster-acting,
killing the cells within 4 h, providing further evidence of their
ability to increase the effectiveness of the encapsulated anti-
biotic. Fig. S19 (ESI†) shows the time-kill results for all the
individual components of the NP. The 0.25 wt% shellac and
0.2 wt% Alcalase NP components alone had only a mild effect
on reducing the viable cell count after 24 h (B1  108 and
1  107 CFU per mL, respectively). The free 0.2 wt% P407 alone
reduced the cell viability concentration to B1  105 CFU per mL
after 24 h, however, when combined with 0.25 wt% shellac
(0.25 wt% shellac–0.2 wt% P407) empty NPs, the toxicity was
reduced, with B1  108 viable cells per mL detected after
24 h of treatment. This indicates that the complexing of
P407 onto shellac cores reduces the toxicity of this Pluronic
surfactant and that the shellac-NPs are a safer antibiotic
delivery vehicle. Surfactants are intrinsically toxic to life due
to their amphipathic nature which can dissolve lipids in water.
The free P407 demonstrates a bacteriostatic effect against
S. aureus by disrupting the cell membrane, however, the lack
of cell specificity makes them unsuitable for use in a therapeutic
context.
A further investigation into the wt% PenG/Oxa-NPs (2-fold
serial dilutions of the stock treatment) was performed to
elucidate the MIC/MBC of S. aureus after 24 h of treatment.
Fig. 2C shows that PenG-NPs had a minimal inhibitory
concentration (MIC) of 0.015 wt%, a 5-fold improvement of
0.05 wt% for free PenG. The minimal bactericidal concen-
tration (MBC) for PenG-NPs was less than 0.0003 wt%, an
8-fold decreased from free PenG showing 40.1 wt% (due to
its resistance). Oxa-NP and free oxacillin had both MIC and
MBC values of o0.0003 wt% after 24 h (oxacillin sensitive),
however as described above the Oxa-NP showed increased
efficacy by the faster killing of the bacteria. Shellac, P407,
shellac–P407 NPs all had MIC and MBC of 40.25 wt%,
0.2 wt% and 0.25 wt% respectively (stock NP concentrations).
Alcalase showed a MIC of 0.1 wt% and an MBC of 4 0.1 wt%, this
agrees with the time-kill results which show that the free protease
did not have a meaningful impact on cell viability. Table S3 (ESI†)
shows tabulated data for the MIC/MBC results.
Fig. 3 (A) and (B) SEM images of planktonic S. aureus after 24 hours growth (no treatment) and (C), (D) SEM images of S. aureus after 24 hours growth
(0.1 wt% PenG-NPs, 1 hour treatment). 10 nm gold coating. Samples were imaged using a Carl Zeiss Evo-60 (Germany) with a variable pressure
100-micron aperture at 40 Pa. EHT was 20 kV with probe current of 100 pA. Images were captured with Zeiss smartSEM software.
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Fig. 3A and B shows SEM images of untreated planktonic
S. aureus which appear to have good morphology with no visible
NPs on their surface. When compared to Fig. 3C and D in which
planktonic S. aureus was treated for 1 hour with 0.1 wt% PenG-
NPs, there is a clear coating of NPs on the surface of
the bacteria. This provides further evidence of the cationic
NPs adhering to the anionic bacterial cell via electrostatic
interactions. This highly localised concentration of antibiotic
encapsulated NPs is apparently able to overcome the enzymatic
resistance mechanism of the S. aureus. Additionally, we inves-
tigated S. aureus using TEM and EDS (Energy-dispersive X-ray
spectroscopy) elemental mapping. Fig. 4 shows the elemental
distribution of carbon, oxygen, nitrogen and sulphur in S.
aureus. When treated with 0.1 wt% free PenG there is an
increased concentration of sulphur compared to the natural
sulphur concentration contained in the untreated sample. This
indicates the presence of PenG, which contains the element
sulphur in its thiazolidine ring. The sample treated with
0.1 wt% PenG-NPs contains a further increase in sulphur, with
small pockets located where the NP has adhered to the bacterial
cell wall. This further supports the increased concentration of
PenG, highly localised on the cell wall.
We also investigated the beta-lactamase activity of S. aureus
after treatment with either 0.1 wt% PenG, 0.1 wt% PenG-NPs
and 0.2 wt% Alcalase. Fig. 2D shows the beta-lactamase activity
measured in S. aureus cells after 1, 2 and 3 h treatments
(compared to a 3 h S. aureus sample which was untreated).
The activity was obtained from the hydrolysis of nitrocefin
(a beta-lactamase substrate). Fig. S20 (ESI†) shows the nitrocefin
calibration curve. The untreated S. aureus had beta-lactamase of
an enzyme activity of 6 mU per mg protein per min. Interestingly,
there was only a marginal decrease in activity in the free PenG
and PenG-NPs over 3 h, and no discernible difference between
free PenG and PenG-NPs. This indicates that S. aureus is not
actively increasing the production and secretion of the beta-
lactamase during treatment.
This lack of PenG defence activity may explain a mechanism
for why PenG-loaded NPs can be effective against S. aureus,
when an equivalent concentration of free PenG is not. The
bacterial cell is not able to produce enough beta-lactamase
enzyme activity to inhibit the PenG, which is locally delivered
and highly concentrated on the cell surface, leached by the
adhered PenG-NPs. Fig. S21 (ESI†) shows the beta-lactamase
activity S. aureus cell and the culture media (containing any
secreted enzyme). There is no notable difference in beta-
lactamase activity of S. aureus when treated with either free
PenG or PenG-NPs (both 0.1 wt%) between 1 h and 3 h. The
effect of 0.2 wt% Alcalase was also investigated. There is a
marginal decrease in beta-lactamase activity after 3 h, com-
pared to the control, 0.1 wt% PenG and 0.1 wt% PenG-NPs,
which are almost identical. This is likely due to the Alcalase
hydrolysing a small amount of beta-lactamase produced by the
bacteria, and therefore lowering the detected enzymatic activity.
This provides evidence that the Alcalase itself can confer benefits
in the context of reducing a beta-lactamase producing bacteria’s
resistance mechanism.
Next, we investigated the effectiveness of the 0.1 wt% PenG/
Oxa NPs on S. aureus biofilms. Biofilms were grown in 96-well
plates for 24 h, and then treated with free antibiotic and
antibiotic-loaded shellac NPs for further 24 h. Fig. 5A and B
show the residual biofilm after staining the wells with Crystal
Violet (CV). Compared to the control of an untreated biofilm,
Fig. 4 TEM/EDS images/scans of S. aureus after 24 hour treatment with either 0.1 wt% PenG or 0.1 wt% PenG-NPs. TEM images were obtained using
a JEM 2010 (JOEL, Japan) at 120 kV and a Gatan Ultrascan 4000 digital camera. A nanoanalysis X-Max 65-T detector and the INCA software were used
to produce the elemental analysis maps. White scale bar = 250 nm.
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there was a B90% biofilm reduction for both 0.1 wt% PenG-
NPs and 0.1 wt% Oxa-NPs treatments. The treatment with
0.1 wt% free PenG showed no significant reduction in residual
biofilm, due doubly to the resistance of S. aureus to this
antibiotic and the protection a biofilm confers to exogenous
treatments. 0.1 wt% free Oxa reduced the biofilm by B50%
compared to the growth control, significantly less the 90%
achieved by the 0.1 wt% Oxa-NPs. The 0.25 wt% shellac and
0.2 wt% P407 showed only a negligible reduction in residual
biofilm in the wells. The 0.2 wt% Alcalase reduced the biofilm
to B50% compared to the growth control, likely due to the
protease activity degrading the EPS matrix protein structure.
Fig. S22 (ESI†) shows images of the biofilm wells with the CV
staining, there is a clear reduction in staining in the 0.1 wt%
PenG/Oxa-NPs compared to the 0.1 wt% free antibiotics.
Fig. 5C and D show the biofilm mass after treatment, where
the results corroborate the ones obtained with CV staining.
Again, the 0.1 wt% PenG-NPs reduced the biofilm mass signifi-
cantly (B1 mg compared to the B3.4 mg untreated control).
The free PenG showed only a marginal reduction of B0.5 mg
due to the resistance of S. aureus.
The 0.1 wt% Oxa-NPs reduced the biofilm mass to 0.3 mg, a
significant improvement against 0.1 wt% free Oxa which
reduced the mass to B1.1 mg. The shellac, P407 and Alcalase
showed a similar trend when measuring the biofilm mass to
the biofilm stained with CV. Fig. 5E and F measured the protein
concentration of the biofilms after treatment. Fig. S23 (ESI†)
shows the BCA calibration curve used to interpolate protein
concentration in the samples. The 0.1 wt% PenG/Oxa-NP treat-
ments reduced the protein concentration to B150–100 mg mL1,
respectively, significantly more than the B800 mg mL1 for
0.1 wt% free PenG and 0.1 wt% B400 mg mL1 for free Oxa.
The 0.2 wt% Alcalase treatment alone was effective in reducing
protein concentration (B500 mg mL1). A time and concentration-
dependent examination of the free 0.1 wt% PenG/Oxa treatments
vs. the 0.1 wt% PenG/Oxa-NPs was performed. Fig. 5G shows that
free PenG (at 0.1, 0.05 and 0.025 wt% concentrations) was no
discernable effect at reducing the residual biofilm. In comparison,
the PenG-NPs after 24 h had reduced the residual biofilm to
B20%. After 1 h the reduction was B40% lower compared to no
treatment indicating the antibiotic-loaded NPs are fast-acting
on the biofilms. There was a very little difference between the
0.025 wt% and the 0.1 wt% stock NPs treatment. This reveals that
the PenG-NPs remain potent at lower concentrations. Fig. 5H
shows the time and concentration-dependent free Oxa vs. Oxa-
NPs. There is a similar trend in the effectiveness of the Oxa-NPs
(across 0.1, 0.05 and 0.025 wt% concentrations), with the residual
biofilm being reduced by B90% compared to no treatment after
24 h. The free Oxa showed a gradual reduction in residual biofilm
over 24 h, culminating in a reduction of 20%, 50% and 60% in
Fig. 5 The effect of (A), (C) and (E) 0.25 wt% shellac–0.2 wt% P407–0.1 wt% PenG–0.2 wt% Alcalase and (B), (D), (F) 0.25 wt% shellac–0.2 wt% P407–
0.1 wt% Oxa–0.2 wt% Alcalase treatments on S. aureus biofilms after 24 h. Residual biofilm staining, biofilm mass and protein concentration respectively.
0.1 wt% PenG/Oxa-NP; 0.25 wt% shellac–0.2 wt% P407–0.1 wt% PenG/Oxa–0.2 wt% Alcalase. o0.05, **P o 0.01, ***P o 0.001 compared to the free
antibiotic. Table S5 (ESI†) shows the statistical analysis P-values. (G) Residual biofilm (CV staining) after treatment with shellac–P407–ABX formulations
after 1, 2, 4 and 24 h treatment times. Treatments were made from a stock of 0.25 wt% shellac–0.2 wt% P407–0.1 wt% PenG–0.02 wt% Alcalase (referred
as PenG-NP) or (H) 0.25 wt% shellac–0.2 wt% P407–0.1 wt% Oxa–0.02 wt% Alcalase (referred as Oxa-NP) and diluted 2-fold. All tests were performed in
triplicates (N = 3 with  S.D.).
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residual biofilm for the 0.1, 0.05 and 0.025 wt% free Oxa treat-
ments. We also investigated the viability of the cells within the
biofilm after 1, 6 and 24 h treatments. Fig. 6A shows the results
after 1 h. The untreated control, 0.25 wt% shellac and 0.2 wt%
P407 showed no reduction in cell viability, with all samples
retaining B1  109 CFU per mL. The results were similar in the
enumeration of the biofilm cells after 6 and 24 h, respectively.
0.1 wt% free PenG showed no reduction in viable cells, however, the
0.1 wt% free Oxa had reduced the cells to B1  107 CFU per mL.
The 0.1 wt% PenG/Oxa-NPs showed a significant improve-
ment compared to the free antibiotic, reducing the viable cells
to B1  106 CFU per mL.
Fig. 6B shows the viable cells after 6 h of treatment. Both the
0.1 wt% PenG and Oxa-NPs reduced the viable cells to B1  102
CFU per mL. 0.1 wt% PenG remained unchanged compared to the
untreated control, the 0.1 wt% free Oxa treatment has reduced the
viable cells to B1  105 CFU per mL. The 0.2 wt% Alcalase
treatment had reduced the viable cells to B1  106 CFU per mL,
likely due to the degradation of the biofilm by the protease
releasing cells from biofilm. Fig. 6C shows the viable cells after
24 h. There were no detectable cells in the 0.1 wt% PenG/Oxa-
NP treatments, a significant reduction compared to B1  109
CFU per mL for the 0.1 wt% free PenG and B1  104 CFU per
mL for the free Oxa. After 24 h treatment with 0.2 wt% Alcalase
the viable cells were reduced to B1  105 CFU per mL. These
results indicate that both the 0.1 wt% PenG-NPs and the
0.1 wt% Oxa-NPs are significantly more effective then and
equivalent concentration of the free antibiotic. Crucially, the
0.1 wt% PenG-NP being effective against a strain of S. aureus
classified as resistant to PenG. Fig. 6D shows fluorescence
microscopy images of the biofilms stained with Acridine
Orange (AO) after 24 h treatment. It is clear to see that there
is a much-decreased concentration in cells in the PenG/Oxa-NP
treatment compared to the control, 0.25 wt% shellac and
0.2 wt% P407 treatments. The 0.1 wt% free PenG remains
relatively unchanged compared to the untreated sample, with
Fig. 6 24 h grown S. aureus biofilm cellular viability after anti-biofilm treatments. CFU per mL of colony biofilms after timed exposure after (A) 1 hour,
(B) 6 hours and (C) 24 hours. Post-treatment, the colony biofilms were glass bead beaten in 1 mL of MHB with serial dilutions. 0.1 wt% ABX = NP; 0.25 wt%
shellac–0.2 wt% P407–0.1 wt% PenG/Oxa-0.2 wt% Alcalase. The agar drop plate method was used to elucidate the CFU per mL. N = 3 with S.D. o0.05,
**P o 0.01, ***P o 0.001 compared to the free antibiotic. Table S6 (ESI†) shows the statistical analysis P-values. (D) Fluorescent images of S. aureus
biofilm stained with Acridine Orange after 24 h of treatment. The white inset bar represents 5 mm.
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0.1 wt% free Oxa and 0.2 wt% Alcalase reducing the AO staining
by B50%. Fig. S24 (ESI†) shows the percentage of AO orange
staining per sample.
The treatment/biofilm growth media was also examined. It
is known that cells within biofilms are able to disperse during a
biofilms natural formation.19 Fig. S25 (ESI†) shows the number
of viable cells after 24 h treatments as described in Fig. 6A. The
untreated control and 0.25 wt% shellac contained B1  104
CFU per mL, much lower than the B1  109 CFU per mL than
found in the biofilms. Biofilms treated with 0.2 wt% and
0.2 wt% Alcalase had fewer cells, B1  103 CFU per mL, likely
due to the moderate cytotoxic nature of these compounds.
0.1 wt% PenG treatment produced B1  104 CFU per mL
due to the resistance of S. aureus to this antibiotic. Treatment
with 0.1 wt% free Oxa treatment showed no viable cells in the
media. No viable cells were also found in the treatment media
of biofilms treated with 0.1 wt% PenG/Oxa-NPs. These results
mirror the CFU counts of planktonic cells shown in Fig. 2. This
indicated that the ABX-NP treatments are able to effectively kill
cells within a biofilm and planktonic cells outside. It is worth
noting that metabolically inactive persister cells are known to
be present in biofilms.47 These cells are very difficult to culture
Fig. 7 Confocal laser scanning microscopy. S. aureus 24 h grown biofilms treated for 1 or 24 h with various treatments. Biofilms were stained with
0.2 wt% Acridine Orange for 5 mins in darkness before gently washing away. The white inset bar represents 50 mm. 0.1 wt% PenG-NP and 0.1 wt% Oxa-
NP refers to 0.25 wt% shellac–0.2 wt% P407–0.1 wt% PenG–0.2 wt% Alcalase NPs and 0.25 wt% shellac–0.2 wt% P407–0.1 wt% Oxa–0.2 wt% Alcalase
NPs. Confocal laser scanning microscopy images (CLSM) were obtained with a Carl Zeiss LSM 710 confocal microscope with Z-series images taken in
1 mm slices.
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and highly tolerant to antibiotics which target a metabolic
mechanism, such as beta-lactam antibiotics. Therefore it is
possible that some cells survived treatment but were not
detected during enumeration.
Fig. 8 (A) Cryostat lateral 10 mm sliced images of S. aureus biofilms after 24 h treatments. Images were taken a 200 magnification. (B) Biofilm
thickness measured over three locations (illustrated with yellow arrows) in Image J v1.52a. 0.1 wt% PenG-NPs and 0.1 wt% Oxa-NPs refers to 0.25 wt%
shellac–0.2 wt% P407–0.1 wt% PenG–0.2 wt% Alcalase NPs and 0.25 wt% shellac–0.2 wt% P407–0.1 wt% Oxa–0.2 wt% Alcalase NPs.
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To understand the structure of the biofilm after treatment
we used confocal laser scanning microscopy (CLSM) to image
S. aureus biofilms stained with AO. Fig. 7 shows images of
S. aureus after 1 h and 24 h treatments as administered in
Fig. 6. The images show that 0.25 wt% and 0.1 wt% PenG had
very little effect on the structure or thickness of the biofilms
compared to the control, which was untreated. 0.2 wt% P407
and 0.2 wt% Alcalase treatments showed some reduction in
biofilm thickness, more notably after 24 h of treatment. The
structure appears less dense particularly on the surface of the
biofilm. 0.1 wt% PenG had very little effect on the S. aureus
PenG resistant biofilm, which agrees with the CV staining and
the CFU viability counts. 0.1 wt% Oxa showed a slightly
decreased thickness and less dense structure after 24 h
of treatment. The 0.1 wt% PenG/Oxa-NPs showed a much-
improved reduction in biofilm mass in comparison the anti-
biotics alone at equivalent concentrations. There appears to the
patches of completely cleared biofilm indicating the NPs are
able to degrade the biofilm and reveal the cells within. The NPs
showed most reduction after 24 h, confirming the CFU viability
counts in Fig. 6. Crucially, the PenG-NPs were effective against a
species with PenG resistance. To further collaborate the CSLM
3D images we cryosectioned 10 mm slices of the membrane
biofilm and examined the thickness and structure of the EPS
matrix with concanavalin A (ConA) dye under brightfield and
fluorescent microscopy. Samples were treated for 24 h before
examination. Fig. 8A shows the biofilm lateral structure and
Fig. 8B shows the thickness of the sectioned biofilms measured
across 3 standardised sections of the image. The sections
show a densely packed biofilm, in the control (untreated) and
0.25 wt% shellac sections (57 mm and 59 mm, respectively). The
thickness is reduced when treated with 0.2 wt% P407 and
0.2 wt% Alcalase (40 mm and 38 mm) which is consistent with
the CSLM results. 0.1 wt% PenG showed very little change from
the untreated control and 0.25 wt% shellac treatment, with a
thickness of 55 mm. Treatment with 0.1 wt% Oxa reduced the
mass to 40 mm. The samples treated with 0.1 wt% PenG/Oxa-
NPs showed a completely cleared biofilm with no ConA staining
detected. This agrees with CFU viability count results in Fig. 6.
The reduction is also consistent with the much-reduced
biofilm mass seen in Fig. 7 using CLSM. The biofilm remnants
still visible in the 3D image is likely due to the differences in
visualisation techniques, 3D visualisation vs. 2D cryo-sectioned
lateral fluorescent imaging. However, both Fig. 7 and 8A both
provide visual support to the CFU viability counts and provide
evidence the PenG/Oxa-NPs are much more effective biofilm
clearing treatments than equivalent concentration of the
free antibiotic. This provides evidence that formulations based
on NP-encapsulated antibiotics with targeted delivery could be
a useful tool in repurposing old antibiotics. This option is becom-
ing increasingly attractive in the antibiotic resistance era.48,49
A preliminary human cell cytotoxicity experiment was per-
formed on HaCaT and HEP G2 cells to investigate if the shellac,
P407, free Alcalase, free PenG/Oxa and PenG/Oxa-NPs were
toxic to human cells. HaCaT cells were chosen as they a good
proxy for studying human keratinocytes, a cell type which
would be exposed to the treatment in topical applications.
HEP G2 were chosen as they are good proxy for studying the
effects of xenobiotics. A full analysis can be found in the ESI.†
Conclusions
In summary, we have developed an innovative nanocarrier
system with a protease coating which can overcome an
antibiotic-resistant pathogen in both planktonic and biofilm
form. We demonstrate the effectiveness of Penicillin G and
oxacillin encapsulated in shellac NPs against a strain of
S. aureus verified as Penicillin G resistant. The functionalisation
of the NPs with a coating of the cationic protease Alcalase
creates a dual application NPs which allows the degradation of
the biofilms and electrostatic adhesion to the anionic bacterial
cell wall. The attachment of the antibiotic-loaded NPs to the
bacterial cells allows a highly localised continuous release of
concentrated antibiotic on the bacteria cell wall which is much
higher than an equivalent concentration of the free antibiotic.
Note that the Alcalase coating allows the antibiotic-packed
nanocarriers to reach the bacterial cells which are ‘‘deeply
buried’’ in the biofilm matrix. This novel method of bacteria-
targeting active NPs with an additional anti-biofilm function
offers an important opportunity to revive the usefulness of
antibiotics considered obsolete (i.e. Penicillin G) and target
biofilm embedded bacteria which are particularly prevalent in
chronic wounds. We conclude that Alcalase-coated and PenG/
Oxa-loaded shellac NPs are an effective and safe method of
clearing antibiotic resistant biofilms, and propose this could be
an alternative approach to topical biofilm treatments, particu-
larly in chronic wounds. We believe that further experimental
investigation into the application of these NPs on biofilm-
infected chronic wounds is required, and could provide a new
therapeutic approach for treating antibiotic resistant biofilms.
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